Cardiff Oncology completed a registered equity financing, entering securities purchase agreements with institutional investors and certain insiders. The company sold 8,571,429 shares with accompanying warrants at $1.05 per share and warrant, for approximately $10.05 million in gross proceeds, and added insider participation for 721,649 shares at $1.455 with matching warrants. Warrants are exercisable after the later of six months or an authorized share increase and run for 5.5 years once exercisable. Cardiff also engaged H.C. Wainwright as exclusive placement agent, including a 7.0% cash fee and agent warrants, to help execute the offering. Proceeds will fund working capital and general corporate needs.
Agreement 1: Cardiff Oncology Raises $10.05 Million in Registered Offering of Common Stock and Warrants
- Agreement type: Securities purchase agreement for registered offering of common stock and warrants
- Counterparty: Institutional investors
- Signed / Effective: Jul 14 2026 / Jul 16 2026
- Duration / Termination: N/A
- Reason: Raise working capital and general corporate purposes
Agreement 2: Cardiff Oncology Adds Insider Participation in Registered Stock-and-Warrant Offering
- Agreement type: Insider securities purchase agreement for registered offering of common stock and warrants
- Counterparty: Company officers and directors
- Signed / Effective: Jul 14 2026 / Jul 16 2026
- Duration / Termination: N/A
- Reason: Demonstrate insider support and raise capital
Agreement 3: Cardiff Oncology Engages H.C. Wainwright as Placement Agent for Equity Offering
- Agreement type: Placement agent engagement for registered equity offering
- Counterparty: H.C. Wainwright & Co.
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: N/A
- Reason: Facilitate placement and execution of equity financing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.